Literature DB >> 26220636

Changing Trends in Treatment of Acute Mania: Experience of a Tertiary Centre Over a Decade.

Mehmet Kemal Arıkan1, Cana Aksoy Poyraz2, Alper Baş1, N Gamze Usta Sağlam1, Gizem Cetiner Batun1, Gözde Gültekin1, Burç Çağrı Poyraz1.   

Abstract

We investigated trends over a decade in the prescription of lithium, antiepileptics, and antipsychotic agents at discharge for patients hospitalised for acute mania. We conducted a retrospective review of medical records for 165 inpatients with acute mania who had been hospitalised in Cerrahpaşa Faculty of Medicine, Department of Psychiatry during 2001-2002 and 2011-2012. Among 165 patients, prescription of olanzapine at discharge increased from 3 to 46 % (p < 0.001), while prescription of haloperidol decreased from 55 to 21 % (p < 0.001). Use of other atypical antipsychotics did not change significantly (risperidone decreased from 14 to 11 %, p = 0.5; quetiapine increased from 10 to 16 %, p = 0.2). Use of valproate, carbamazepine, and lithium did not change significantly. Use of electroconvulsive therapy in acute mania decreased by half from 27 to 13 % (p = 0.02). Typical antipsychotics alone or in combination with antiepileptics were the most common treatment regimen at discharge at 2001-2002; while 10 years later, they had been largely replaced by lithium or antiepileptics combined with second generation antipsychotics. Antipsychotic agents remained to be an important component of acute treatment of mania in our practice.

Entities:  

Keywords:  Acute mania; Bipolar disorder; ECT; Pharmacotherapy

Mesh:

Substances:

Year:  2016        PMID: 26220636     DOI: 10.1007/s11126-015-9388-9

Source DB:  PubMed          Journal:  Psychiatr Q        ISSN: 0033-2720


  36 in total

1.  Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013.

Authors:  Lakshmi N Yatham; Sidney H Kennedy; Sagar V Parikh; Ayal Schaffer; Serge Beaulieu; Martin Alda; Claire O'Donovan; Glenda Macqueen; Roger S McIntyre; Verinder Sharma; Arun Ravindran; L Trevor Young; Roumen Milev; David J Bond; Benicio N Frey; Benjamin I Goldstein; Beny Lafer; Boris Birmaher; Kyooseob Ha; Willem A Nolen; Michael Berk
Journal:  Bipolar Disord       Date:  2012-12-12       Impact factor: 6.744

2.  Pharmacological treatment of acute mania in psychiatric in-patients between 1994 and 2004.

Authors:  Marcus Wolfsperger; Waldemar Greil; Wulf Rössler; Renate Grohmann
Journal:  J Affect Disord       Date:  2006-09-20       Impact factor: 4.839

3.  Trends in pharmacotherapy in patients referred to a bipolar specialty clinic, 2000-2011.

Authors:  Farnaz Hooshmand; Shefali Miller; Jennifer Dore; Po W Wang; Shelley J Hill; Natalie Portillo; Terence A Ketter
Journal:  J Affect Disord       Date:  2013-11-21       Impact factor: 4.839

4.  Olanzapine compared to lithium in mania: a double-blind randomized controlled trial.

Authors:  M Berk; L Ichim; S Brook
Journal:  Int Clin Psychopharmacol       Date:  1999-11       Impact factor: 1.659

5.  Aripiprazole adjunct treatment in bipolar I or II disorder, depressed state: a 2-year clinical study.

Authors:  Rao N Malempati
Journal:  J Nerv Ment Dis       Date:  2015-01       Impact factor: 2.254

6.  The use of quetiapine for treatment-resistant bipolar disorder: a case series.

Authors:  S N Ghaemi; J J Katzow
Journal:  Ann Clin Psychiatry       Date:  1999-09       Impact factor: 1.567

7.  Suicide risk in bipolar disorder during treatment with lithium and divalproex.

Authors:  Frederick K Goodwin; Bruce Fireman; Gregory E Simon; Enid M Hunkeler; Janelle Lee; Dennis Revicki
Journal:  JAMA       Date:  2003-09-17       Impact factor: 56.272

8.  Antipsychotic medication utilization trends among Texas veterans: 1997-2002.

Authors:  Min Yang; Jamie C Barner; Kenneth A Lawson; Karen L Rascati; James P Wilson; M Lynn Crismon; Jason Worchel; Cynthia A Mascarenas
Journal:  Ann Pharmacother       Date:  2008-08-05       Impact factor: 3.154

9.  A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder.

Authors:  Guy M Goodwin; Charles L Bowden; Joseph R Calabrese; Heinz Grunze; Siegfried Kasper; Robin White; Paul Greene; Robert Leadbetter
Journal:  J Clin Psychiatry       Date:  2004-03       Impact factor: 4.384

10.  Clinical and neurocognitive predictors of functional outcome in bipolar euthymic patients: a long-term, follow-up study.

Authors:  C M Bonnín; A Martínez-Arán; C Torrent; I Pacchiarotti; A R Rosa; C Franco; A Murru; J Sanchez-Moreno; E Vieta
Journal:  J Affect Disord       Date:  2009-06-07       Impact factor: 4.839

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.